A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and Valganciclovir combination

Abstract Multicentric Castleman disesase (MCD) is a lymphoproliferative disorder characterized by systemic symptoms like recurrent lymphadenopathy, fever and hepatosplenomegaly. Human herpes virus 8 (HHV-8) can be associated with MCD whether the patient is infected with human immunodeficiency virus...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2016-07, Vol.22 (7), p.483-485
Main Authors: Nuhoglu Kantarci, Fatma Eda, Eren, Rafet, Gündoğdu, Cihan, Huq, Gülben Erdem, Doğu, Mehmet Hilmi, Suyanı, Elif
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Castleman disease
Castleman Disease - drug therapy
Castleman Disease - pathology
Castleman Disease - virology
Cyclophosphamide - therapeutic use
Drug Therapy, Combination
Etoposide - therapeutic use
Ganciclovir - analogs & derivatives
Ganciclovir - therapeutic use
Hematology, Oncology and Palliative Medicine
Herpesviridae
Herpesvirus
Herpesvirus 8, Human - isolation & purification
Human herpes virus 8
Human herpesvirus 8
Human immunodeficiency virus
Humans
Lentivirus
Male
Middle Aged
Multicentric Castleman disease
Prednisolone - therapeutic use
Rituximab - therapeutic use
Treatment
Valganciclovir
Vincristine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Multicentric Castleman disesase (MCD) is a lymphoproliferative disorder characterized by systemic symptoms like recurrent lymphadenopathy, fever and hepatosplenomegaly. Human herpes virus 8 (HHV-8) can be associated with MCD whether the patient is infected with human immunodeficiency virus (HIV) or not. A 59-year-old male patient presented with fatigue, drowsiness and enlarged lymph nodes. Thoracic and abdominal computed tomography showed enlarged mediastinal, axillary, paracardiac, paraaortic, celiac, mesenteric, obturator and inguinal lymph nodes concomitant with enlarged liver and spleen. Cervical lymph node biopsy revealed HHV-8 positive plasma cell MCD. The patient’s tests were negative for HIV. R-CEOP (rituximab, cyclophosphamide, etoposid, vincristin, prednisolone) and valganciclovir treatments were started simultaneously. After sixth cycle of R-CEOP, the patient achieved uncorfimed complete remission. Rituximab combined with CEOP protocol and antiviral therapy against HHV-8 might be an effective therapeutic approach without a considerable side effect for HHV-8-positive HIV-negative MCD patients.
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2016.01.002